Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Upstream Bio, Inc.NASDAQ: UPB

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 54.33M shares rose 1.3% year over year, behind the +4.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.3% toward the trailing-twelve-month pace of +4.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
54.33M+0.2% QoQ
Last fiscal yearDec 2025
53.85M+4.9% YoY
LTMMar 2026
54.07M+4.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%——
1 year+4.9%——
3-year CAGR+14.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
53.85M USD
Year-over-year change
+4.9%
3-year CAGR
+14.0%

Weighted Avg Shares (Diluted) vs competitors

How UPB compares with its peers on the latest reported figures

  • UPB's LTM Mar 2026 weighted avg shares (diluted) of 54.07M shares is the 9th highest of the 10 companies compared; the peer median is 110.2M shares.
  • Its year-over-year change of +4.2% is the 8th highest of 10, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of +14.0% compares with a peer median of +15.2%.
UPB Competitors Peer median
Weighted Avg Shares (Diluted) for UPB and competitors
Company Period LTM YoY 3-year CAGR
RLAYRelay Therapeutics, Inc.LTM Jun 2026181.67M +12.1%+15.2%
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
NVAXNovavax, Inc.LTM Mar 2026168.99M +1.8%+30.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026108.82M +29.3%+12.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
UPBUpstream Bio, Inc.LTM Mar 202654.07M +4.2%+14.0%
ZBIOZenas BioPharma, Inc.LTM Mar 202646.54M +13.7%+5.3%
Peer median (excluding UPB) 110.2M+13.7%+15.2%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.